{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"PBYI","limit":50},"count":50,"signals":[{"ticker":"PBYI","company":"PUMA BIOTECHNOLOGY, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":80,"context":"l responsibility for global development and commercialization. Our development of alisertib will be expensive, lengthy and unpredictable, and any failure to successfully develop alisertib will have a material adverse effect on our business and financial position. | | | | | Interim, toplineand preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data becom","filed_date":"2026-02-26","accession":"0001437749-26-005891","full_text":"https://origin.rootz.global/static/filing/0001437749-26-005891.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PBYI","company":"PUMA BIOTECHNOLOGY, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":19,"context":"rogram, each non-employee director receives an annual cash retainer for service on the Board, and for service on each committee of which the non-employee director is a member, paid in four equal installments at the beginning of each calendar quarter. All cash fees are payable on a pro-rated basis for non-employee directors who are initially elected or appointed in the middle of a calendar quarter. Th","filed_date":"2025-04-28","accession":"0001437749-25-013337","full_text":"https://origin.rootz.global/static/filing/0001437749-25-013337.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PBYI","company":"PUMA BIOTECHNOLOGY, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":16,"context":"d approves any related party transactions. | | | | | The Compensation Committee oversees and assesses whether any of our compensation plans, policies, and programs are reasonably likely to have a material adverse effect on us. | | | | | The Nominating and Corporate Governance Committee oversees and reviews with management risks relating to governance matters, including succession planning, as well as business et","filed_date":"2025-04-28","accession":"0001437749-25-013337","full_text":"https://origin.rootz.global/static/filing/0001437749-25-013337.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PBYI","company":"PUMA BIOTECHNOLOGY, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":96,"context":"tify the selection of KPMG LLP as our independent registered public accounting firmfor the year ending December 31, 2025; | | | | 3. | Vote on an advisory basis to approve the compensation of our Named Executive Officers as described in the proxy statement (say-on-pay vote); and | | | | 4. | Transact such other business as may properly come before the annual meeting. | | The accompanying Notice of Annual Meetin","filed_date":"2025-04-28","accession":"0001437749-25-013337","full_text":"https://origin.rootz.global/static/filing/0001437749-25-013337.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PBYI","company":"PUMA BIOTECHNOLOGY, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":17,"context":"rt (n=5) represent patients who had brain metastases which were amenable to surgery and who were administered neratinib monotherapy prior to and after surgical resection. The third cohort (target enrollment=60) enrolled two sub-groups of patients (prior lapatinib-treated and no prior lapatinib) with progressive brain metastases who were administered neratinib in combination with the chemotherapy drug","filed_date":"2025-02-27","accession":"0001437749-25-005496","full_text":"https://origin.rootz.global/static/filing/0001437749-25-005496.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PBYI","company":"PUMA BIOTECHNOLOGY, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":79,"context":"l responsibility for global development and commercialization. Our development of alisertib will be expensive, lengthy and unpredictable, and any failure to successfully develop alisertib will have a material adverse effect on our business and financial position. | | | | | Interim, toplineand preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data becom","filed_date":"2025-02-27","accession":"0001437749-25-005496","full_text":"https://origin.rootz.global/static/filing/0001437749-25-005496.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PBYI","company":"PUMA BIOTECHNOLOGY, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":16,"context":"d approves any related party transactions. | | | | | The Compensation Committee oversees and assesses whether any of our compensation plans, policies, and programs are reasonably likely to have a material adverse effect on us. | | | | | The Nominating and Corporate Governance Committee oversees and reviews with management risks relating to governance, environmental and social responsibility matters, including su","filed_date":"2024-04-26","accession":"0001437749-24-013309","full_text":"https://origin.rootz.global/static/filing/0001437749-24-013309.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PBYI","company":"PUMA BIOTECHNOLOGY, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":90,"context":"tify the selection of KPMG LLP as our independent registered public accounting firmfor the year ending December 31, 2024; | | | | 3. | Vote on an advisory basis to approve the compensation of our named executive officers as described in the proxy statement (say-on-pay vote); | | | | 4. | Vote on an advisory basis regarding the frequency of future say-on-pay votes (frequency vote); | | | | 5. | Approve an ame","filed_date":"2024-04-26","accession":"0001437749-24-013309","full_text":"https://origin.rootz.global/static/filing/0001437749-24-013309.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PBYI","company":"PUMA BIOTECHNOLOGY, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":18,"context":"rt (n=5) represent patients who had brain metastases which were amenable to surgery and who were administered neratinib monotherapy prior to and after surgical resection. The third cohort (target enrollment=60) enrolled two sub-groups of patients (prior lapatinib-treated and no prior lapatinib) with progressive brain metastases who were administered neratinib in combination with the chemotherapy drug","filed_date":"2024-02-29","accession":"0001437749-24-006121","full_text":"https://origin.rootz.global/static/filing/0001437749-24-006121.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PBYI","company":"PUMA BIOTECHNOLOGY, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":82,"context":"l responsibility for global development and commercialization. Our development of alisertib will be expensive, lengthy and unpredictable, and any failure to successfully develop alisertib will have a material adverse effect on our business and financial position. | | | | | Interim, toplineand preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data becom","filed_date":"2024-02-29","accession":"0001437749-24-006121","full_text":"https://origin.rootz.global/static/filing/0001437749-24-006121.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PBYI","company":"PUMA BIOTECHNOLOGY, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":80,"context":"LLP as our independent registered public accounting firm for the year ending December 31, 2023;  | |   |   | 3. | Vote on an advisory basis to approve the compensation of our named executive officers as described in the proxy statement (“say-on-pay vote”); and | |   |   | 4. | Transact such other business as may properly come before the annual meeting. | |   The","filed_date":"2023-04-28","accession":"0001437749-23-011500","full_text":"https://origin.rootz.global/static/filing/0001437749-23-011500.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PBYI","company":"PUMA BIOTECHNOLOGY, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":22,"context":"rt (n=5) represent patients who had brain metastases which were amenable to surgery and who were administered neratinib monotherapy prior to and after surgical resection. The third cohort (target enrollment=60) enrolled two sub-groups of patients (prior lapatinib-treated and no prior lapatinib) with progressive brain metastases who were administered neratinib in combination with the chemotherapy drug","filed_date":"2023-03-02","accession":"0001437749-23-005233","full_text":"https://origin.rootz.global/static/filing/0001437749-23-005233.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PBYI","company":"PUMA BIOTECHNOLOGY, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":46,"context":"l responsibility for global development and commercialization. Our development of alisertib will be expensive, lengthy and unpredictable, and any failure to successfully develop alisertib will have a material adverse effect on our business and financial position. | |   |   | • | Interim, “topline” and preliminary data from our clinical trials that we announce or publish from time","filed_date":"2023-03-02","accession":"0001437749-23-005233","full_text":"https://origin.rootz.global/static/filing/0001437749-23-005233.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PBYI","company":"PUMA BIOTECHNOLOGY, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":17,"context":"s such qualification, except in the case of clause (b) above, where the failure to be so qualified or be in good standing would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the business, properties, financial condition, results of operations or prospects of the Company (a Material Adverse Effect). 4.2** Corporate Power; Authorization.** The Company has full corporate","filed_date":"2022-12-13","accession":"0001437749-22-028937","full_text":"https://origin.rootz.global/static/filing/0001437749-22-028937.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PBYI","company":"PUMA BIOTECHNOLOGY, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":12,"context":"States and in our Phase II SUMMIT basket trial,, and we may experience additional disruptions in those clinical trials or future clinical trials.   Our ability to continue to operate without any significant negative impacts will in part depend on the future severity of the COVID-19 pandemic and our ability to protect our employees and our supply chain. We continue to follow and monitor recommended actions of government","filed_date":"2022-11-03","accession":"0001437749-22-025787","full_text":"https://origin.rootz.global/static/filing/0001437749-22-025787.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PBYI","company":"PUMA BIOTECHNOLOGY, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":17,"context":"s such qualification, except in the case of clause (b) above, where the failure to be so qualified or be in good standing would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the business, properties, financial condition, results of operations or prospects of the Company (a Material Adverse Effect). 4.2** Corporate Power; Authorization.** The Company has full corporate","filed_date":"2022-07-25","accession":"0001437749-22-017633","full_text":"https://origin.rootz.global/static/filing/0001437749-22-017633.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PBYI","company":"PUMA BIOTECHNOLOGY, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":16,"context":"rogram, each non-employee director receives an annual cash retainer for service on the Board, and for service on each committee of which the non-employee director is a member, paid in four equal installments at the beginning of each calendar quarter. All cash fees are payable on a pro-rated basis for non-employee directors who are initially elected or appointed in the middle of a calendar quarter. Th","filed_date":"2022-04-29","accession":"0001437749-22-010271","full_text":"https://origin.rootz.global/static/filing/0001437749-22-010271.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PBYI","company":"PUMA BIOTECHNOLOGY, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":68,"context":"ify the selection of KPMG LLP as our independent registered public accounting firm for the year ending December 31, 2022; | | | | 3. | Vote on an advisory basis to approve the compensation of our named executive officers as described in the proxy statement (say-on-pay vote); and | | | | 4. | Transact such other business as may properly come before the annual meeting. | | The accompanying Notice of Annual Meetin","filed_date":"2022-04-29","accession":"0001437749-22-010271","full_text":"https://origin.rootz.global/static/filing/0001437749-22-010271.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PBYI","company":"PUMA BIOTECHNOLOGY, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":32,"context":"rt (n=5) represent patients who had brain metastases which were amenable to surgery and who were administered neratinib monotherapy prior to and after surgical resection. The third cohort (target enrollment=60) enrolled two sub-groups of patients (prior lapatinib-treated and no prior lapatinib) with progressive brain metastases who were administered neratinib in combination with the chemotherapy drug","filed_date":"2022-03-03","accession":"0001437749-22-005164","full_text":"https://origin.rootz.global/static/filing/0001437749-22-005164.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PBYI","company":"PUMA BIOTECHNOLOGY, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":32,"context":"lone or in combination with other approved products or investigational new drugs that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any, as applicable. | |   |   | • | NERLYNX is still under clinical development for various additional indications, and we cannot be certain tha","filed_date":"2022-03-03","accession":"0001437749-22-005164","full_text":"https://origin.rootz.global/static/filing/0001437749-22-005164.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PBYI","company":"PUMA BIOTECHNOLOGY, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"ishment costs |   |   | (8,519 | ) |   |   | — |   | | | Payment of debt issuance costs |   |   | (1,910 | ) |   |   | — |   | | | Installment payment for purchase of intangible asset |   |   | (20,000 | ) |   |   | — |   | | | Net cash (used in) provided by financing activities |   |   | (31,929","filed_date":"2021-11-04","accession":"0001437749-21-025298","full_text":"https://origin.rootz.global/static/filing/0001437749-21-025298.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PBYI","company":"PUMA BIOTECHNOLOGY, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":17,"context":"rogram, each non-employee director receives an annual cash retainer for service on the Board, and for service on each committee of which the non-employee director is a member, paid in four equal installments at the beginning of each calendar quarter. All cash fees are payable on a pro-rated basis for non-employee directors who are initially elected or appointed in the middle of a calendar quarter. Th","filed_date":"2021-04-26","accession":"0001564590-21-020547","full_text":"https://origin.rootz.global/static/filing/0001564590-21-020547.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PBYI","company":"PUMA BIOTECHNOLOGY, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":65,"context":"an Stuglik, and Troy E. Wilson; | | | | 2. | Ratify the selection of our independent registered public accounting firm; | | | | 3. | Vote on an advisory basis to approve the compensation of our named executive officers as described in the proxy statement (say-on-pay vote); | | | | 4. | Approve an amendment (the Auerbach Warrant Amendment) to the terms of the warrant, issued to Alan H. Auerbach, President and Ch","filed_date":"2021-04-26","accession":"0001564590-21-020547","full_text":"https://origin.rootz.global/static/filing/0001564590-21-020547.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PBYI","company":"PUMA BIOTECHNOLOGY, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":20,"context":"ort (n5) represent patients who had brain metastases which were amenable to surgery and who were administered neratinib monotherapy prior to and after surgical resection. The third cohort (target enrollment60) enrolled two sub-groups of patients (prior lapatinib-treated and no prior lapatinib) with progressive brain metastases who were administered neratinib in combination with the chemotherapy drug","filed_date":"2021-03-01","accession":"0001564590-21-009840","full_text":"https://origin.rootz.global/static/filing/0001564590-21-009840.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PBYI","company":"PUMA BIOTECHNOLOGY, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":33,"context":"lone or in combination with other approved products or investigational new drugs that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any, as applicable. | | | | | NERLYNX is still under clinical development for various additional indications, and we cannot be certain that NERLYNX will receive r","filed_date":"2021-03-01","accession":"0001564590-21-009840","full_text":"https://origin.rootz.global/static/filing/0001564590-21-009840.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PBYI","company":"PUMA BIOTECHNOLOGY, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":66,"context":"s to serve for a one-year term; | | | | 2. | Ratify the selection of our independent registered public accounting firm; | | | | 3. | Vote on an advisory basis to approve the compensation of our named executive officers as described in the proxy statement (say-on-pay vote); and | | | | 4. | Transact such other business as may properly come before the annual meeting. | | The accompanying Notice of Annual Meeting","filed_date":"2020-04-27","accession":"0001193125-20-120969","full_text":"https://origin.rootz.global/static/filing/0001193125-20-120969.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PBYI","company":"PUMA BIOTECHNOLOGY, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":22,"context":"ld suffer financial and reputational harm or other negative outcomes, including possible legal consequences. Any termination, breach or expiration of any of these sub-license agreements could have a material adverse effect on our financial position by reducing or eliminating the potential for us to receive license fees, milestones and royalties. In such an event, we may be required to devote additional efforts and to i","filed_date":"2020-02-28","accession":"0001564590-20-007591","full_text":"https://origin.rootz.global/static/filing/0001564590-20-007591.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PBYI","company":"PUMA BIOTECHNOLOGY, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":60,"context":"s to serve for a one-year term; | | | | 2. | Ratify the selection of our independent registered public accounting firm; | | | | 3. | Vote on an advisory basis to approve the compensation of our named executive officers as described in the proxy statement (say-on-pay vote); and | | | | 4. | Transact such other business as may properly come before the annual meeting. | | The accompanying Notice of Annual Meeting","filed_date":"2019-04-29","accession":"0001193125-19-125238","full_text":"https://origin.rootz.global/static/filing/0001193125-19-125238.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PBYI","company":"PUMA BIOTECHNOLOGY, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":21,"context":"rcement authorities. The costs of defending such claims, as well as any sanctions imposed or negative public perceptions resulting therefrom, could require us to restructure our operations and have a material adverse effect on our financial performance. Similar rigid restrictions are imposed on the promotion and marketing of medicinal products in the EU and other countries. Laws (including those governing promotion, ma","filed_date":"2019-03-01","accession":"0001564590-19-005830","full_text":"https://origin.rootz.global/static/filing/0001564590-19-005830.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PBYI","company":"PUMA BIOTECHNOLOGY, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":66,"context":"s to serve for a one-year term; | | | | 2. | Ratify the selection of our independent registered public accounting firm; | | | | 3. | Vote on an advisory basis to approve the compensation of our named executive officers as described in the proxy statement (say-on-pay vote); | | | | 4. | Vote on an advisory basis regarding the frequency of future say-on-pay votes (frequency vote); and | | | | 5. | Transact suc","filed_date":"2018-04-30","accession":"0001193125-18-143106","full_text":"https://origin.rootz.global/static/filing/0001193125-18-143106.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PBYI","company":"PUMA BIOTECHNOLOGY, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":19,"context":"rcement authorities. The costs of defending such claims, as well as any sanctions imposed or negative public perceptions resulting therefrom, could require us to restructure our operations and have a material adverse effect on our financial performance. 26 Similar rigid restrictions are imposed on the promotion and marketing of medicinal products in the EU and other countries. Laws (including those governing promotion,","filed_date":"2018-03-09","accession":"0001564590-18-005152","full_text":"https://origin.rootz.global/static/filing/0001564590-18-005152.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PBYI","company":"PUMA BIOTECHNOLOGY, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":18,"context":"estimated. While complete assurance cannot be given to the outcome of these proceedings, management does not currently believe that any of these matters, individually or in the aggregate, will have a material adverse effect on the Companys financial condition, liquidity or results of operations. Legal Proceedings Hsu vs. Puma Biotechnology, Inc., et. al. On June 3, 2015, Hsingching Hsu or the plaintiff, individually and","filed_date":"2017-11-09","accession":"0001564590-17-023226","full_text":"https://origin.rootz.global/static/filing/0001564590-17-023226.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PBYI","company":"PUMA BIOTECHNOLOGY, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":18,"context":"estimated. While complete assurance cannot be given to the outcome of these proceedings, management does not currently believe that any of these matters, individually or in the aggregate, will have a material adverse effect on the Companys financial condition, liquidity or results of operations. Legal Proceedings Hsu vs. Puma Biotechnology, Inc., et. al. On June 3, 2015, Hsingching Hsu, individually and on behalf of all","filed_date":"2017-08-09","accession":"0001564590-17-016942","full_text":"https://origin.rootz.global/static/filing/0001564590-17-016942.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PBYI","company":"PUMA BIOTECHNOLOGY, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":59,"context":"on, except as indicated herein, no arrangements or understandings exist between any director or person nominated for election as a director and any other person pursuant to whom such person is to be selected as a director or nominee for election as a director. 9 [Table of Contents](#toc) **CORPORATE GOVERNANCE** **Board Leadership Structure and Role in Risk Oversight** Alan H. Auerbach currently serves as our Chairm","filed_date":"2017-04-28","accession":"0001193125-17-148435","full_text":"https://origin.rootz.global/static/filing/0001193125-17-148435.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PBYI","company":"PUMA BIOTECHNOLOGY, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":17,"context":"rcement authorities. The costs of defending such claims, as well as any sanctions imposed or negative public perceptions resulting therefrom, could require us to restructure our operations and have a material adverse effect on our financial performance. Similar rigid restrictions are imposed on the promotion and marketing of medicinal products in the EU and other countries. Laws (including those governing promotion, ma","filed_date":"2017-03-01","accession":"0001564590-17-003090","full_text":"https://origin.rootz.global/static/filing/0001564590-17-003090.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PBYI","company":"PUMA BIOTECHNOLOGY, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":17,"context":"l or otherwise, or in the earnings, business affairs or business prospects of the Company and its Subsidiary considered as one enterprise, whether or not arising in the ordinary course of business (a Material Adverse Effect), (B) there have been no transactions entered into by the Company and its Subsidiary, other than those in the ordinary course of business, which are material with respect to the Company and its Subsi","filed_date":"2016-10-21","accession":"0001193125-16-743948","full_text":"https://origin.rootz.global/static/filing/0001193125-16-743948.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PBYI","company":"PUMA BIOTECHNOLOGY, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":48,"context":"on, except as indicated herein, no arrangements or understandings exist between any director or person nominated for election as a director and any other person pursuant to whom such person is to be selected as a director or nominee for election as a director. 9 [Table of Contents](#toc) **CORPORATE GOVERNANCE** **Board Leadership Structure and Role in Risk Oversight** Alan H. Auerbach currently serves as our Chairm","filed_date":"2016-04-29","accession":"0001193125-16-565802","full_text":"https://origin.rootz.global/static/filing/0001193125-16-565802.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PBYI","company":"PUMA BIOTECHNOLOGY, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":17,"context":"rcement authorities. The costs of defending such claims, as well as any sanctions imposed or negative public perceptions resulting therefrom, could require us to restructure our operations and have a material adverse effect on our financial performance. Other Laws and Regulatory Processes We are subject to a variety of financial disclosure and securities trading regulations as a public company in the United States wit","filed_date":"2016-02-29","accession":"0001564590-16-013716","full_text":"https://origin.rootz.global/static/filing/0001564590-16-013716.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PBYI","company":"PUMA BIOTECHNOLOGY, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":62,"context":"90049. At this years annual meeting you will be asked to: | | 1. | Elect four directors to serve for a one-year term; | | | | 2. | Vote on an advisory basis to approve the compensation of our named executive officers as described in the proxy statement (say-on-pay vote); | | | | 3. | Ratify the selection of our independent registered public accounting firm; | | | | 4. | Approve an amendment to the Puma Bio","filed_date":"2015-04-30","accession":"0001193125-15-157767","full_text":"https://origin.rootz.global/static/filing/0001193125-15-157767.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PBYI","company":"PUMA BIOTECHNOLOGY, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":16,"context":"rcement authorities. The costs of defending such claims, as well as any sanctions imposed or negative public perceptions resulting therefrom, could require us to restructure our operations and have a material adverse effect on our financial performance. 18 Manufacturing We do not currently have our own manufacturing facilities. We intend to continue to use our financial resources to accelerate development of our drug","filed_date":"2015-03-02","accession":"0001564590-15-001193","full_text":"https://origin.rootz.global/static/filing/0001564590-15-001193.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PBYI","company":"PUMA BIOTECHNOLOGY, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":17,"context":"l or otherwise, or in the earnings, business affairs or business prospects of the Company and its Subsidiary considered as one enterprise, whether or not arising in the ordinary course of business (a Material Adverse Effect), (B) there have been no transactions entered into by the Company and its Subsidiary, other than those in the ordinary course of business, which are material with respect to the Company and its Subsi","filed_date":"2015-01-22","accession":"0001193125-15-017655","full_text":"https://origin.rootz.global/static/filing/0001193125-15-017655.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PBYI","company":"PUMA BIOTECHNOLOGY, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":52,"context":"scular regenerative medicine company, and Integrated Diagnostics, Inc., a privately-held molecular diagnostics company, since January 2011 and March 2011, respectively. In January 2013, Mr. Moyes was appointed to the board of directors of Amedica Corporation, a privately-held orthopedic implant company, which is now a public company. He was subsequently appointed Chief Financial Officer in October 2013 and remains a member of the","filed_date":"2014-04-30","accession":"0001193125-14-172013","full_text":"https://origin.rootz.global/static/filing/0001193125-14-172013.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PBYI","company":"PUMA BIOTECHNOLOGY, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":14,"context":"rcement authorities. The costs of defending such claims, as well as any sanctions imposed or negative public perceptions resulting therefrom, could require us to restructure our operations and have a material adverse effect on our financial performance. **Manufacturing** We do not currently have our own manufacturing facilities. We intend to continue to use our financial resources to accelerate development of our drug","filed_date":"2014-03-03","accession":"0001193125-14-080183","full_text":"https://origin.rootz.global/static/filing/0001193125-14-080183.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PBYI","company":"PUMA BIOTECHNOLOGY, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":21,"context":"s](#toc) to May 2011. Mr. Auerbach received a B.S. in Biomedical Engineering from Boston University and an M.S. in Biomedical Engineering from the University of Southern California. Mr. Auerbach was selected as a director because of his position as our President and Chief Executive Officer and his significant experience as an executive and research analyst in the biotechnology industry. *Thomas R. Malley*. Mr. Malley","filed_date":"2013-04-30","accession":"0001193125-13-187398","full_text":"https://origin.rootz.global/static/filing/0001193125-13-187398.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PBYI","company":"PUMA BIOTECHNOLOGY, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"to use the PFS data from the trial as the basis for submission of an NDA/MAA for Accelerated/Conditional Approval for PB272 from the regulatory agencies. We anticipate that we will begin patient enrollment in this Phase III trial in the second quarter of 2013. In 2010, Pfizer also initiated a Phase I/II trial of neratinib in combination with the anti-cancer drug temsirolimus, or Torisel, in patients","filed_date":"2013-04-01","accession":"0001193125-13-136650","full_text":"https://origin.rootz.global/static/filing/0001193125-13-136650.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PBYI","company":"PUMA BIOTECHNOLOGY, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":13,"context":"reimbursement for our products or are significantly delayed in doing so, we will have difficulty achieving market acceptance of our products and expected revenue and profitability which would have a material adverse effect on our business, results of operations and financial condition. **We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse and false claims laws and regulations. Pr","filed_date":"2013-04-01","accession":"0001193125-13-136650","full_text":"https://origin.rootz.global/static/filing/0001193125-13-136650.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PBYI","company":"PUMA BIOTECHNOLOGY, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":23,"context":"ber 2010 to May 2011. Mr. Auerbach received a B.S. in Biomedical Engineering from Boston University and an M.S. in Biomedical Engineering from the University of Southern California. Mr. Auerbach was selected as a director because of his position as our President and Chief Executive Officer and his significant experience as an executive and research analyst in the biotechnology industry. ** *Charles R. Eyler*. Mr. Eyle","filed_date":"2013-04-01","accession":"0001193125-13-136650","full_text":"https://origin.rootz.global/static/filing/0001193125-13-136650.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PBYI","company":"PUMA BIOTECHNOLOGY, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":12,"context":"reimbursement for our products or are significantly delayed in doing so, we will have difficulty achieving market acceptance of our products and expected revenue and profitability which would have a material adverse effect on our business, results of operations and financial condition. **We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse and false claims laws and regulations. Pr","filed_date":"2012-11-14","accession":"0001193125-12-469037","full_text":"https://origin.rootz.global/static/filing/0001193125-12-469037.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PBYI","company":"PUMA BIOTECHNOLOGY, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":12,"context":"reimbursement for our products or are significantly delayed in doing so, we will have difficulty achieving market acceptance of our products and expected revenue and profitability which would have a material adverse effect on our business, results of operations and financial condition. **We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse and false claims laws and regulations. Pr","filed_date":"2012-10-24","accession":"0001193125-12-433444","full_text":"https://origin.rootz.global/static/filing/0001193125-12-433444.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PBYI","company":"PUMA BIOTECHNOLOGY, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":13,"context":"rights of third parties. If we are sued for infringing intellectual property rights of third parties, it will be costly and time consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business. | | | | | | Prior to this offering, there has been a limited public market for our common stock, and there can be no assurance that a regular trading market will develop and cont","filed_date":"2012-10-17","accession":"0001193125-12-426109","full_text":"https://origin.rootz.global/static/filing/0001193125-12-426109.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"06f694b38223cd5ccab730fcb296eb121d416e2ffbbdc2150076d73681b6ab10","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"05e252cacab4f2f1b192bd8402fb0fdade1a02ca5c42d769e7a5274b6acb6fcd","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256() || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":3,"hourly_limit":500,"remaining":497,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}